These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 25874605)

  • 41. Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents.
    Sato H; Kato T; Arawaka S
    Mol Neurobiol; 2015 Aug; 52(1):226-35. PubMed ID: 25143237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
    Mahul-Mellier AL; Fauvet B; Gysbers A; Dikiy I; Oueslati A; Georgeon S; Lamontanara AJ; Bisquertt A; Eliezer D; Masliah E; Halliday G; Hantschel O; Lashuel HA
    Hum Mol Genet; 2014 Jun; 23(11):2858-79. PubMed ID: 24412932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells.
    Gao J; Perera G; Bhadbhade M; Halliday GM; Dzamko N
    J Biol Chem; 2019 Sep; 294(39):14241-14256. PubMed ID: 31375560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Release and uptake of pathologic alpha-synuclein.
    Grozdanov V; Danzer KM
    Cell Tissue Res; 2018 Jul; 373(1):175-182. PubMed ID: 29411106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic Effects of Milk-Derived Exosomes and Galactose on
    Melnik BC
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DJ-1 deficiency impairs autophagy and reduces alpha-synuclein phagocytosis by microglia.
    Nash Y; Schmukler E; Trudler D; Pinkas-Kramarski R; Frenkel D
    J Neurochem; 2017 Dec; 143(5):584-594. PubMed ID: 28921554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropathology of α-synuclein propagation and braak hypothesis.
    McCann H; Cartwright H; Halliday GM
    Mov Disord; 2016 Feb; 31(2):152-60. PubMed ID: 26340605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses.
    Jan A; Gonçalves NP; Vaegter CB; Jensen PH; Ferreira N
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading.
    Loria F; Vargas JY; Bousset L; Syan S; Salles A; Melki R; Zurzolo C
    Acta Neuropathol; 2017 Nov; 134(5):789-808. PubMed ID: 28725967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.
    Arotcarena ML; Teil M; Dehay B
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease.
    Yu S; Chan P
    Essays Biochem; 2014; 56():125-35. PubMed ID: 25131591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
    Savitt D; Jankovic J
    Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.